Deramiocel Slowed Upper Limb Decline in Duchenne Study

Capricor Therapeutics reported data showing a 76% reduction in limb impairment for Duchenne muscular dystrophy patients.

Updated on Oct. 5, 2026 in Biotech

Bold flat-color editorial illustration of a solitary medical vial, symbolizing clinical progress in Duchenne muscular dystrophy treatment. — Capricor Therapeutics submitted new HOPE-3 clinical study data to the FDA, showing a 76% reduction in upper limb functional decline for Duchenne patients. AI Illustration. Upload story photo >

Live Poll

Should the government prioritize fast-track approval for new medical treatments for rare diseases?

Capricor Therapeutics has presented results from the open-label extension of its HOPE-3 clinical study, demonstrating a 76% reduction in the rate of upper limb decline among Duchenne muscular dystrophy patients who transitioned from placebo to treatment. The findings have been submitted to the FDA as an amendment to the company's existing Biologics License Application.

Why it matters

Duchenne muscular dystrophy results from a lack of functional dystrophin in muscle cells, leading to progressive physical impairment. This data marks a significant step in the regulatory review process for a treatment aimed at preserving muscle function in the patient population.

The study tracked 106 randomized patients, with 98 entering the open-label extension. Functional outcomes were measured using the PUL 2.0 total score.

The players

Capricor Therapeutics

A San Diego-based biotechnology company focused on the development of cell and exosome-based therapeutics for rare diseases.

FDA

The United States federal agency responsible for the regulation and approval of biologics and pharmaceuticals.

The details

Researchers evaluated the efficacy of Deramiocel, an experimental therapy, by administering the drug intravenously every three months. The study utilized the PUL 2.0 total score, a clinical assessment tool used to measure upper limb performance, to quantify changes in function. By comparing the rate of decline in patients after they transitioned from a placebo—an inactive substance used as a control—to the treatment, the team observed the 76% deceleration in functional loss.

July 2026: One-year study results were published in The Lancet.
October 5, 2026: Data were presented at the 31st Annual Congress of the World Muscle Society.
October 7, 2026: A webinar to discuss the clinical data is scheduled.
November 22, 2026: The FDA PDUFA target action date is scheduled for a regulatory decision.

The Tech Race

The HOPE-3 trial represents a pivotal milestone in the development pipeline for Duchenne muscular dystrophy therapies. It functions as the primary clinical engine for the current Biologics License Application awaiting FDA action.

The development directly addresses the mobility challenges faced by individuals with Duchenne muscular dystrophy. Availability remains contingent on the upcoming FDA review process.

The takeaway

The study demonstrates a clear slowing of functional decline in patients receiving the therapy. Stakeholders should monitor the FDA decision scheduled for November 22, 2026, to determine the commercial path forward.